These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9007205)

  • 21. Decreased anti-human immunodeficiency virus type-1 activities of 2',3'-dideoxynucleoside analogs in MOLT-4 cell sublines resistant to 2',3'-dideoxynucleoside analogs.
    Cinatl J; Cinatl J; Weber B; Rabenau H; Weissflog A; Mainke M; Kornhuber B; Doerr HW
    Acta Virol; 1993 Oct; 37(5):360-8. PubMed ID: 8184788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors.
    Shafer RW; Winters MA; Iversen AK; Merigan TC
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2887-90. PubMed ID: 9124861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
    Picard V; Angelini E; Maillard A; Race E; Clavel F; Chêne G; Ferchal F; Molina JM
    J Infect Dis; 2001 Sep; 184(6):781-4. PubMed ID: 11517441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
    Brennan TM; Taylor DL; Bridges CG; Leyda JP; Tyms AS
    Antiviral Res; 1995 Mar; 26(2):173-87. PubMed ID: 7541619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
    Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
    Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1].
    Cao YL; Li SX; Chen H; Guo Y
    Yao Xue Xue Bao; 2009 Apr; 44(4):355-61. PubMed ID: 19545051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
    Gao WY; Johns DG; Tanaka M; Mitsuya H
    Mol Pharmacol; 1999 Mar; 55(3):535-40. PubMed ID: 10051538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea.
    Boelaert JR; Sperber K; Piette J
    AIDS Res Hum Retroviruses; 1999 Sep; 15(14):1241-7. PubMed ID: 10505672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude.
    Choi Y; George C; Comin MJ; Barchi JJ; Kim HS; Jacobson KA; Balzarini J; Mitsuya H; Boyer PL; Hughes SH; Marquez VE
    J Med Chem; 2003 Jul; 46(15):3292-9. PubMed ID: 12852759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P
    J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [AIDS therapy with reverse transcriptase inhibitors].
    Mitsuya H
    Nihon Rinsho; 1993 Sep; 51 Suppl():316-26. PubMed ID: 7505849
    [No Abstract]   [Full Text] [Related]  

  • 33. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
    Flandre P; Descamps D; Joly V; Meiffrédy V; Tamalet C; Izopet J; Aboulker JP; Brun-Vézinet F
    Antivir Ther; 2003 Feb; 8(1):65-72. PubMed ID: 12713066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
    Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine.
    Lennerstrand J; Stammers DK; Larder BA
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2144-6. PubMed ID: 11408240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of cycloSal-d4TMP derivatives in H9 cells with induced AZT resistance phenotype.
    Gröschel B; Meier C; Zehner R; Cinatl J; Doerr HW; Cinatl J
    Nucleosides Nucleotides; 1999; 18(4-5):933-6. PubMed ID: 10432712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
    Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
    AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro.
    Albright AV; Erickson-Viitanen S; O'Connor M; Frank I; Rayner MM; González-Scarano F
    AIDS Res Hum Retroviruses; 2000 Oct; 16(15):1527-37. PubMed ID: 11054266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New anti-HIV agents and targets.
    De Clercq E
    Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.